close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Mirum Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.